Ftse Mib
33.986,90
1,06%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.344,70
-1,02%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immunome Inc (IMNM) Immunome Inc (IMNM) Notizie

Immunome Inc

IMNM
16,00
0,25 (1,59%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:19:48
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202414:00BWImmunome Appoints Kinney Horn as Chief Business Officer
25/4/202414:26BWImmunome Appoints Sandra M. Swain to Board of Directors
05/4/202414:00BWImmunome to Present Preclinical Data for IM-3050, Its Lead..
28/3/202421:02BWImmunome Reports Full Year 2023 Financial Results and..
26/3/202413:00BWImmunome Completes Acquisition of AL102, a Phase 3 Asset for..
07/3/202414:00BWImmunome to Participate in the Leerink Partners Global..
01/3/202414:00BWImmunome to Participate in the TD Cowen 44th Annual..
22/2/202403:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:07EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/2/202414:15BWImmunome Recognizes Ayala Pharmaceuticals’ Announced..
16/2/202422:05BWImmunome Announces Closing of Public Offering and Full..
14/2/202422:11EDGAR2Form 8-K - Current report
14/2/202422:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202404:38BWImmunome Announces Pricing of Public Offering of Common..
13/2/202422:36EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202422:10EDGAR2Form 8-K - Current report
13/2/202422:05BWImmunome Announces Proposed Public Offering of Common Stock
12/2/202420:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202414:05EDGAR2Form 8-K - Current report
05/2/202414:00BWImmunome to Present at the Guggenheim Healthcare Talks 6th..
02/2/202422:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/2/202402:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202423:27EDGAR2Form 8-K - Current report
08/1/202413:05EDGAR2Form 8-K - Current report
08/1/202413:00BWImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
04/1/202423:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202414:00BWImmunome Appoints Phil Roberts as Chief Technical Officer
03/1/202414:00BWImmunome to Present at the 42nd Annual J.P. Morgan..
02/1/202414:05EDGAR2Form 8-K - Current report
02/1/202414:00BWImmunome Appoints Carol A. Schafer to Board of Directors
29/12/202323:00EDGAR2Form 8-K - Current report
26/12/202314:35EDGAR2Form 8-K - Current report
26/12/202314:30GLOBEAtreca Announces Asset Purchase Agreement for Sale of..
16/12/202301:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202303:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202322:02EDGAR2Form 8-K/A - Current report: [Amend]
16/11/202322:08EDGAR2Form S-3 - Registration statement under Securities Act of..
15/11/202312:03EDGAR2Form 8-K - Current report
10/11/202314:00BWImmunome to Present at the Stifel 2023 Healthcare Conference
09/11/202322:52EDGAR2Form 8-K - Current report
09/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:00BWImmunome Reports Third Quarter 2023 Financial Results
08/11/202314:30EDGAR2Form 8-K - Current report
08/11/202314:00BWImmunome Appoints Jean-Jacques Bienaimé to Board of..
31/10/202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202323:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202314:00BWImmunome Appoints Bob Lechleider, M.D., as Chief Medical..
Apertura: 15,75 Min: 15,12 Max: 16,1799
Chiusura: 15,75

La tua Cronologia

NASDAQ
IMNM
Immunome
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network